Cost-effectiveness analysis of variceal ligation vs. beta-rockers for primary prevention of variceal bleeding

Hepatology

Volumn 45, Issue 4, 2007, Pages 870-878

  Imperiale, Thomas F ^a,b   Klein, Robert W ^c   Chalasani, Naga ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b REGENSTRIEF INSTITUTE   (United States)

^c Medical Decision Modeling Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; BLEEDING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; ESOPHAGUS VARICES; HEALTH CARE COST; HUMAN; LIGATION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; COST-BENEFIT ANALYSIS; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HUMANS; LIGATION; MODELS, ECONOMIC; QUALITY OF LIFE; VASCULAR SURGICAL PROCEDURES;

EID: 34247370954     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21605     Document Type: Article

References (62)

1. Grace ND. Prevention of initial variceal hemorrhage. Gastroenterol Clin North Am 1992;21:149-161.
2. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 1988;319:983-989.
3. Chalasani N, Kahn C, Francois F, Pinto A, Marathe A, Bini EJ, et al. Outcomes following acute variceal bleeding: a multicenter cohort study. Am J Gastroenterol 2003;98:653-659.
4. Smith JL, Graham DY. Variceal hemorrhage: a critical evaluation of survival analysis. Gastroenterology 1982;82:968-973.
5. Lebrec D, Poynard T, Capron JP, Hillon P, Geoffroy P, Roulot D, et al. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomized trial. J Hepatol 1988;7:118-125.
6. Pascal JP, Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987;317:856-861.
7. Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials, Franco-Italian Multicenter Study Group. N Engl J Med 1991;324:1532-1538.
8. Ideo G, Bellati G, Fesce E, Grimoldi D. Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study. HEPATOLOGY 1988;8:6-9.
9. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a metaanalytic review. HEPATOLOGY 1999;22:332-354.
10. Pagliaro L, D'Amico G, Sorensen TI, Lebrec D, Burroughs AK, Morabito A, et al. Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med 1992;117:59-70.
11. Banares R, Moitinho E, Piqueras B, Casado M, Garcia-Pagan JC, de Diego A, et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. HEPATOLOGY 1999;30:79-83.
12. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: An evidence-based approach. Semin Liver Dis 1999;19:475.
13. Garcia-Pagan JC, Villanueva C, Vila MC. Isosorbide mononitrate in the prevention of first bleed in patients who cannot receive beta-blockers. Gastroenterology 2001;121:908-914.
14. Sarin SK. Long-term management of oesophageal varices. Drugs 1992;44: 56-69.
15. Lebrec D, Bernuau J, Rueff B, Benhamou J-P. Gastrointestinal bleeding after abrupt cessation of propranolol administration in cirrhosis. N Engl J Med 1982;198:307-560.
16. Sarin SK, Guptan RK, Jain AK. A randomized controlled trial of endoscopic variceal band ligation for primary prophylaxis variceal bleeding. Eur J Gastroenterol Hepatol 1996;8:337-342.
17. Lo G-H, Lai K-H, Cheng J-S, Lin C-K, Hsu P-I, Chiang HT. Prophylactic banding ligation of high risk esophageal varices in patients with cirrhosis: A prospective, randomized trial. J Hepatol 1999;31:451-456.
18. Lay CS, Tsai YT, Teg CY, Shyu WS, Guo WS, Wu KL, et al. Endoscopic variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices. HEPATOLOGY 1997;25:1346-1350.
19. De BK, Ghoshal UC, Das T, Santra A, Biswas PK. Endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleed; Preliminary report of a randomized controlled trial. J Gastroenterol Hepatol 1999;14: 220-224.
20. Sarin SK, Lamba GS, Kumar M, Misra A, Murthy NS. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999;340:988-993.
21. Lui HF, Stanley AJ, Forrest EH, Jalan R, Hislop WS, Mills PR, et al. Primary prophylaxis of variceal hemorrhage: A randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. [see comment]. Gastroenterology 2002;123:735-744.
22. Jutabha R, Jensen DM, Martin P, Savides T, Han S-H, Gornbein J. Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high risk esophageal varices. Gastroenterology 2005;128:870-881.
23. Schepke M, Kleber G, Nurnberg D, Willert J, Koch L, Veltzke-Schlieker W, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. HEPATOLOGY 2004;40:65-72.
24. Thuluvath PJ, Maheshwari A, Jagannath S, Arepally A. A randomized controlled trial of beta-blockers versus endoscopic band ligation for primary prophylaxis: A large sample size is required to show a difference in bleeding rates. Dig Dis Sci 2005;50:407-410.
25. Lo G-H, Chen WC, Chen M-H, Lin CP, Lo CC, Hsu P-I, et al. Endoscopic ligation vs nadolol in the prevention of first variceal bleeding in patients with cirrhosis. Gastrointest Endosc 2004;59:333-338.
26. Imperiale TF, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. HEPATOLOGY 2001;33:802-807.
27. Khuroo MS, Khuroo NS, Farahat KLC, Khuroo YS, Sofi AA, Dahab ST. Meta-analysis: Endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Aliment Pharmacol Ther 2005;21:347-361.
28. Aoki N, Kajiyama T, Beck R, Cone RW, Soma K, Fukui T. Decision analysis of prophylactic treatment for patients with high-risk esophageal varices. Gastrointest Endosc 2000;52:707-714.
29. Arguedas MR, Heudebert GR, Eloubeidi MA, Abrams GA, Fallon MB. Cost-effectiveness of screening, surveillance, and primary prophylaxis sttategies for esophageal varices. Am J Gastroenterol 2002;97:2441-2452.
30. Saab S, DeRosa V, Nieto J, Dutazo F, Han S, Roth B. Costs and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: A decision analytic model. Am J Gastroenterol 2003;98: 763-770.
31. Spiegel BMR, Targownik L, Dulai GS, Karsan HA, Gralnek IM. Endoscopic screening for esophageal varices in cirrhosis: Is it ever cost effective? HEPATOLOGY 2003;37:366-377.
32. Teran JC, Imperiale TF, Mullen KD, Tavill AS, McCullough AJ. Primary prophylaxis of variceal bleeding in cirrhosis: A cost effectiveness analysis. Gastroenterology 1997;112:473-482.
33. de Franchis R. Endoscopy critics vs. endoscopy enthusiasts for primary prophylaxis of variceal bleeding. HEPATOLOGY 2006;43:24-26.
34. Sanyal AJ, Freedman AM, Luketic VA, et al. Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology 1996;111:138-146.
35. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
36. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981;80:800-809.
37. Burroughs AK. The natural history of varices. J Hepatol 1993;17(Suppl 2):S10-S13.
38. Grace ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. Am J Gastroenterol 1997;92:1081-1091.
39. Grace ND, Groszmann RJ, Garcia-Tsao G, Burroughs AK, Pagliaro L, Makulah RW, et al. Portal hypertension and variceal bleeding: An AASLD single topic symposium. HEPATOLOGY 1998;28:868-880.
40. de la Pena J, Brullet E, Sanchez-Hernandez E, Rivero M, Vergara M, Marrin-Lorente JL, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. HEPATOLOGY 2005;41:572-578.
41. Lo G-H, Lai K-H, Cheng J-S, Chen M-H, Huang H-C, Hsu P-I, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: A prospective, randomized trial. HEPATOLOGY 2000;32:461-465.
42. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-454.
43. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV concensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167-176.
44. Grace ND, Garcia-Pagan JC, Angelico M, Moreau R, Albillos A, Schepke M, et al. Primary prophylaxis for variceal bleeding: Blackwell Publishing, 2006.
45. Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346:1056-1059.
46. Grace ND. Hemodynamic assessment of pharmacological response in the treatment of portal hypertension: a need ro know. Am J Gastroenterol 2000;95:1862-1864.
47. Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, et al. The hemodynamic response to medical treatment of portal hypertension as a predicror of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. HEPATOLOGY 2000;32:930-934.
48. Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Torras X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996;334:1624-1629.
49. Imperiale TF, Chalasani N, Klein RW. Measuring the hemodynamic response to primary pharmacoprophylaxis of variceal bleeding: A cost-effectiveness analysis. Am J Gastroenterol 2003;98:2742-2750.
50. Chalasani N, Hurlander JC Jr, Said A, Hoen H, Kopecky K, Stockberger S, et al. Screening for hepatocellular carcinoma in patients with cirrhosis. Am J Gastroenterol 1999;94:2988-2993.
51. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-S50.
52. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. HEPATOLOGY 2006;43:1303-1310.
53. Sanyal AJ, Banas C, Satgeant C, Luketic VA, Sterling RK, Stravitz RT, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. HEPATOLOGY 2006;43:682-689.
54. Jalan R, Bzeizi KI, Tripathi D, Lui HF, Redhead DN, Hayes PC. Impact of transjugular intrahepatic portosystemic stent-shunt for secondary prophylaxis of oesophageal variceal haemorrhage: a single-centre study over an 11-year period. Eur J Gastroenterol Hepatol 2002;14:615-626.
55. Vangeli M, Patch D, Burroughs AK. Salvage tips for uncontrolled variceal bleeding. J Hepatol 2002;37:703-704.
56. Merkel C, Bolognesi M, Angeli P, Noventa F, Caregaro L, Sacerdoti D, et al. Prognostic indicators of survival in patients with cirrhosis and esophageal varices without previous bleeding. Am J Gastroenterol 1989;84:717-722.
57. Thein H-H, Krahn M, Kaldor JM, Dole GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol 2005;100:643-651.
58. Wells CD, Murrill WB, Arguedas MR. Comparison of health-related quality of life preferences between physicians and cirrhotic patients: implications for cost-utility analyses in chronic liver disease. Dig Dis Sci 2004;49: 453-458.
59. AMA Current Procedural Terminology; CPT 2001, Standard Edition. Chicago: AMA Press, 2001.
60. Zaman A, Goldberg RJ, Pettit KG, Kaniecki DJ, Benner K, Zacker C, et al. Cost of treating an episode of variceal bleeding in a VA setting. Am J Gastroenterol 2000;95:1323-1330.
61. Russo MW, Zacks SL, Sandler RS, Brown RS. Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding. HEPATOLOGY 2000;31:358-363.
62. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-1258.